GlassScriptPhysician profile
Alisa Khurgin
NPI 1750907150
$2,217.57
in general payments reported to CMS, 2019-2025
17 companies · $146 in 2025
The $146 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $263 · 2022: $200 · 2023: $597 · 2024: $1,012 · 2025: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,754.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,754.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $478.26 | 2023-2025 | |
| Biotissue Holdings INC. | $290.85 | 2021-2024 | |
| Alcon Vision LLC | $265.18 | 2021-2024 | Clareon, Argos, Eysuvis |
| Johnson & Johnson Vision Care, INC. | $253.57 | 2022-2023 | Acuvue |
| Sun Pharmaceutical Industries INC. | $134.53 | 2023-2024 | Cequa |
| Rxsight INC | $132.86 | 2024 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Bausch & Lomb Americas INC. | $129.78 | 2023-2025 | Xiidra, Miebo, Scoutpro Osmolarity System |
| Coopervision INC. | $111.94 | 2021-2025 | Misight Contact Lens |
| Horizon Therapeutics Plc | $81.28 | 2023 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $75.43 | 2024 | Xdemvy |
| Harrow Eye, LLC | $70.67 | 2024 | Vevye |
| Novartis Pharmaceuticals Corporation | $66.51 | 2022-2023 | |
| Allergan, INC. | $41.99 | 2021-2022 | |
| Tearlab Corp | $34.93 | 2024 | Scoutpro Osmolarity System |
| Dompe US, INC. | $20.94 | 2024 | Oxervate |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $15.50 | 2024 | Ryzumvi, Tyrvaya |
| Eyevance Pharmaceuticals LLC | $13.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alisa Khurgin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.